RIABNI
Biological
Amgen Inc.
Total Payments
$37,081
Transactions
21
Doctors
11
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $105.22 | 5 | 4 |
| 2023 | $37.33 | 2 | 2 |
| 2022 | $1,408 | 4 | 3 |
| 2021 | $4,335 | 3 | 2 |
| 2020 | $31,195 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $33,833 | 8 | 91.2% |
| Consulting Fee | $2,458 | 3 | 6.6% |
| Travel and Lodging | $400.00 | 1 | 1.1% |
| Food and Beverage | $390.21 | 9 | 1.1% |
Payments by Type
Research
$33,833
8 transactions
General
$3,248
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Global 52 wk Study with q6 month Infusion of ABP 798 or Rituximab | Amgen Inc. | $20,983 | 0 |
| Study Evaluating Safety and Efficacy of ABP 798 Compared with Rituximab in Subjects with NHL | Amgen Inc. | $12,850 | 0 |
Top Doctors Receiving Payments for RIABNI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Zanesville, OH | $33,833 | 8 |
| , MD | Hematology | Memphis, TN | $1,298 | 1 |
| , M.D | Internal Medicine | Boston, MA | $1,160 | 2 |
| , M.D | Rheumatology | Dallas, TX | $400.00 | 1 |
| Richard Brasington | — | Saint Louis, MO | $123.83 | 1 |
| , MD | Rheumatology | Saint Louis, MO | $123.83 | 1 |
| , MD | Internal Medicine | San Juan, PR | $39.32 | 2 |
| , M.D | Hematology & Oncology | Mayaguez, PR | $25.03 | 1 |
| , M.D | Hematology & Oncology | San Juan, PR | $20.87 | 1 |
| , M.D | Pediatrics | Los Angeles, CA | $20.85 | 1 |
| , M.D | Hematology & Oncology | San Juan, PR | $20.00 | 1 |
| , M.D | Oncology | San Juan, PR | $16.48 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $37,081
Product Information
- Type Biological
- Total Payments $37,081
- Total Doctors 11
- Transactions 21
About RIABNI
RIABNI is a biological associated with $37,081 in payments to 11 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2020 to 2024. In 2024, $105.22 was paid across 5 transactions to 4 doctors.
The most common payment nature for RIABNI is "Unspecified" ($33,833, 91.2% of total).
RIABNI is associated with 2 research studies, including "Global 52 wk Study with q6 month Infusion of ABP 798 or Rituximab" ($20,983).